Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies

Justin H. Hwang1, Nicholas Zorko1, Andrew Elliott2, John R. Lozada1, Milan Radovic1, Elisabeth I. Heath4, Neeraj Agarwal3, Rana R. McKay5, Rohan Garje6, Bruno R. Bastos6, Dave SB. Hoos1, Chadi Nabnab7, George Sledge9, Emmanuel S. Antonarakis1

1 Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN. 2 Caris Life Sciences, Phoenix, AZ. 3 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 4 Karmanos Cancer Institute, Detroit, MI, USA. 5 UC San Diego, La Jolla, CA, USA. 6 Miami Cancer Institute, Baptist Health South Florida, Miami, FL. 7 Saint Johns Cancer Institute Phil, Santa Monica, CA.

Abstract

Background: B7-H3 (CD276) is a transmembrane glycoprotein of the B7 superfamily that includes PD-L1 and CTLA-4. B7-H3 targeted therapeutics are challenging to drug. The spectrum of B7-H3 (CD276) transcriptional expression across human malignancies is a pan-tumor target. We demonstrate B7-H3 to be a promising pan-tumor target, and that targeting B7-H3 is highly expressed in cancers with driver mutations lacking effective precision therapies.

Methods: RNA (FQI genes/whole-exome) and DNA (whole-transcriptome) sequencing was performed for samples submitted to Caris Life Sciences (Phoenix, AZ). Differential expression of individual genes was analyzed, with pathway enrichment assessed by Gene Set Enrichment Analyses (GSEA). mRNA and DNA deconvolution was used to estimate immune cell infiltration of tumor microenvironments using quanTraiing (Finotello, 2019). Real-world overall survival (OS) was determined from insurance claims data and Kaplan-Meier estimates were calculated. Statistical significance was determined using X2 and Mann-Whitney U tests with Bonferroni-Hochberg corrections for multiple hypothesis testing where appropriate.

Results: B7-H3 mRNA displayed robust expression in many prevalent cancer types, including prostate, pancreatic, breast, colorectal, ovarian, and lung cancers. High B7-H3 expression predicted worse OS in head & neck cancers (1.291 HR, 95% CI 1.096–1.52, p=0.002) and lung adenocarcinoma (1.247 HR, 95% CI 1.16–1.34, p=0.0001). Notably, high B7-H3 was associated with differential rates of alterations in TP53, RB1, and KRAS in several cancer types. When examining Hallmark gene signatures, we found that B7-H3-high samples demonstrated consistent enrichment for pathways associated with epithelial to mesenchymal transition (EMT), TGF-Beta, and Notch signaling (FDR<0.05) across several cancer types. Additionally, we found high B7-H3 expression to be correlated with PD-L1 expression, as well as greater proportions of pro-inflammatory M1 macrophages but lower proportions of effector CD8+ T cells.

Conclusion: We demonstrate B7-H3 to be a promising pan-tumor target, with most solid tumors showing robust expression that is often associated with worse OS. In several major cancers, high B7-H3 expression was associated with mutational and transcriptomic repertoires not easily targeted by current precision therapies. We find that B7-H3-high tumors to have increased potential for myeloid-driven immune induction, making them potentially more amenable to immunomodulatory therapies, in particular, those targeting B7-H3. Further work is warranted to elucidate different mechanistic interactions of B7-H3 with specific oncogenic pathways in each cancer type.

Figure 1. B7-H3 expression was determined in 93,861 tumors in over 45 cancer types, Transcripts Per Million (TPM) is displayed after log normalization.

Figure 2. Top – The association of high B7-H3 expression with overall survival across cancers. Bottom – Kaplan-Meier curves for select cancer types displaying significant associations between B7-H3 expression and overall survival. OS data was collected from insurance claims.

Figure 3. B7-H3 is expressed alongside driver mutations lacking effective precision therapies

Figure 4. GSEA analysis with functional oncogenic pathways on B7-H3-high vs-low tumors. Normalized enrichment scores (NES) are displayed.

Figure 5. Associations of B7-H3 expression with well-established predictors of immunotherapy response across selected cancer types.

Figure 6. B7-H3-high tumors displayed altered immune repertoires based on immune fraction estimations using quanTraiing.

Study Highlights

- B7-H3 is highly expressed in cancers with genomic and transcriptomic alterations that are challenging to drug.
- B7-H3 expression is independent of current immunotherapy biomarkers, but is associated with distinct immune landscapes.
- In major cancer types, B7-H3 is consistently associated with signaling pathways including EMT, TGF-Beta, and Notch Signaling.

Contact: Justin Hwang, Ph.D. jhwang@umn.edu
Emmanuel Antonarakis, M.D. antonar403@umn.edu
Twitter @Antonarakis